Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 2/20 | 0.49 |
| ▸ | ADH5 | P11766 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743779 | 0.80 | ALDH1A1 (0.56) | ALDH1A1RARBADH5XDHSLC22A12 | |
| SCHEMBL5249400 | 0.79 | ALDH1A1 (0.44) | ALDH1A1RARBADH5XDHSLC22A12 | |
| SCHEMBL31546329 | 0.78 | ALOX5 (0.61) | ALDH1A1RARBADH5XDHSLC22A12 | |
| SCHEMBL2646011 | 0.78 | ALDH1A1 (0.58) | ALDH1A1RARBADH5XDHSLC22A12 | |
| SCHEMBL2646013 | 0.77 | ALDH1A1 (0.57) | ALDH1A1RARBADH5XDHSLC22A12 | |
| SCHEMBL15059787 | 0.77 | ALDH1A1 (0.57) | ALDH1A1RARBADH5XDHSLC22A12 | |
| SCHEMBL1099755 | 0.77 | ALDH1A1 (0.32) | ALDH1A1XDH | |
| SCHEMBL750501 | 0.77 | ALDH1A1 (0.57) | ALDH1A1RARBADH5XDHSLC22A12 | |
| SCHEMBL18603158 | 0.77 | ALDH1A1 (0.57) | ALDH1A1RARBADH5XDHSLC22A12 | |
| SCHEMBL2963261 | 0.77 | ALDH1A1 (0.61) | ALDH1A1RARBADH5XDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | claimed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2021067569-A1 | SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| EP-2183239-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-22 | — | — | EP | claimed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | claimed |
| EP-2183239-A1 | SULFONAMIDES AS TRPM8 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2010-05-12 | — | — | EP | claimed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | claimed |
| WO-2009012430-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-22 | — | — | WO | claimed |
| US-5627197-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-05-06 | — | — | US | claimed |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | disclosed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2021067569-A1 | SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-9434711-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2016-09-06 | — | — | US | disclosed |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-23 | — | — | US | disclosed |
| EP-2150539-A1 | PYRIDAZINONE DERIVATIVES | Merck Patent GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009012430-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008145243-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-5627197-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-05-06 | — | — | US | disclosed |
| EP-0727425-A1 | Adhesion receptor antagonists | MERCK PATENT GmbH (DE) | 1996-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | CDK5, CDK5R1, PKD1 | ALDH1A1 2375/4885RARB 4754/4885ADH5 4282/4885 |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | ALDH1A1 3091/4885RARB 1164/4885ADH5 3338/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | ALDH1A1 3091/4885RARB 1164/4885ADH5 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.